Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Hims & Hers Health Inc a un objectif de cours consensus de $28.65, basé sur les évaluations des 19 analystes. Le plus élevé est de $68 attribué par Canaccord Genuity le février 19, 2025, et le plus bas est de $10 attribué par Baird le avril 11, 2023. Les 3 dernières évaluations d'analystes ont été publiées par Truist Securities, Truist Securities et Morgan Stanley le août 18, 2025, juillet 17, 2025 et juin 11, 2025. Avec un objectif de cours moyen de $41.67 entre Truist Securities, Truist Securities et Morgan Stanley, il y a une variation implicite de -16.97% downside pour Hims & Hers Health Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Truist Securities
Morgan Stanley
Piper Sandler
Citigroup
B of A Securities
1calculé à partir des notes des analystes
Notes d'analystes pour Hims & Hers Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/18/2025 | -26.27% | Truist Securities | $48 → $37 | Maintains | Hold | |||
08/05/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
07/17/2025 | -4.34% | Truist Securities | $45 → $48 | Maintains | Hold | |||
06/11/2025 | -20.29% | Morgan Stanley | $40 → $40 | Reiterates | Equal-Weight → Equal-Weight | |||
06/04/2025 | 29.53% | Needham | $61 → $65 | Maintains | Buy | |||
05/06/2025 | -22.28% | Piper Sandler | $35 → $39 | Reiterates | Neutral → Neutral | |||
05/06/2025 | -40.22% | Citigroup | $25 → $30 | Maintains | Sell | |||
05/06/2025 | 21.56% | Needham | $61 → $61 | Reiterates | Buy → Buy | |||
04/29/2025 | -48.19% | B of A Securities | $22 → $26 | Maintains | Underperform | |||
04/29/2025 | -20.29% | Morgan Stanley | $60 → $40 | Maintains | Equal-Weight | |||
04/29/2025 | -40.22% | TD Cowen | $44 → $30 | Downgrade | Buy → Hold | |||
04/25/2025 | -50.18% | Citigroup | $27 → $25 | Maintains | Sell | |||
04/10/2025 | -34.24% | Truist Securities | $39 → $33 | Maintains | Hold | |||
03/18/2025 | -56.16% | B of A Securities | $21 → $22 | Maintains | Underperform | |||
03/06/2025 | -58.15% | B of A Securities | $21 → $21 | Reiterates | Underperform → Underperform | |||
03/06/2025 | -46.19% | Citigroup | $27 → $27 | Reiterates | Sell → Sell | |||
02/26/2025 | -22.28% | Truist Securities | $24 → $39 | Maintains | Hold | |||
02/25/2025 | -20.29% | Leerink Partners | $24 → $40 | Maintains | Market Perform | |||
02/25/2025 | -30.25% | Piper Sandler | $24 → $35 | Maintains | Neutral | |||
02/25/2025 | 21.56% | Needham | $31 → $61 | Maintains | Buy | |||
02/25/2025 | -46.19% | Citigroup | $25 → $27 | Maintains | Sell | |||
02/20/2025 | -58.15% | B of A Securities | $18 → $21 | Maintains | Underperform | |||
02/19/2025 | 35.51% | Canaccord Genuity | $38 → $68 | Maintains | Buy | |||
02/18/2025 | 19.57% | Morgan Stanley | $42 → $60 | Downgrade | Overweight → Equal-Weight | |||
01/10/2025 | -50.18% | Citigroup | $24 → $25 | Downgrade | Neutral → Sell | |||
01/07/2025 | -30.25% | BTIG | → $35 | Initiates | → Buy | |||
01/06/2025 | -52.17% | Piper Sandler | $21 → $24 | Maintains | Neutral | |||
01/06/2025 | -38.22% | Needham | $28 → $31 | Maintains | Buy | |||
12/17/2024 | -16.3% | Morgan Stanley | → $42 | Initiates | → Overweight | |||
12/02/2024 | -24.27% | Canaccord Genuity | $28 → $38 | Maintains | Buy | |||
11/20/2024 | -44.2% | TD Cowen | $28 → $28 | Reiterates | Buy → Buy | |||
11/14/2024 | -64.13% | B of A Securities | $32 → $18 | Downgrade | Buy → Underperform | |||
11/08/2024 | -44.2% | TD Cowen | $25 → $28 | Maintains | Buy | |||
11/06/2024 | -46.19% | Deutsche Bank | $23 → $27 | Maintains | Hold | |||
11/05/2024 | -58.15% | Piper Sandler | $18 → $21 | Reiterates | Neutral → Neutral | |||
11/05/2024 | -44.2% | Canaccord Genuity | $24 → $28 | Maintains | Buy | |||
10/21/2024 | -50.18% | B of A Securities | $23 → $25 | Maintains | Buy | |||
10/14/2024 | -54.16% | B of A Securities | $20 → $23 | Maintains | Buy | |||
09/13/2024 | -60.14% | B of A Securities | $24 → $20 | Maintains | Buy | |||
08/22/2024 | -52.17% | Needham | → $24 | Initiates | → Buy | |||
08/07/2024 | -54.16% | Deutsche Bank | $16 → $23 | Maintains | Hold | |||
08/06/2024 | -64.13% | Piper Sandler | $18 → $18 | Reiterates | Neutral → Neutral | |||
07/18/2024 | -54.16% | Truist Securities | $13 → $23 | Maintains | Hold | |||
07/11/2024 | -50.18% | TD Cowen | $15 → $25 | Maintains | Buy | |||
07/11/2024 | -64.13% | Piper Sandler | $16 → $18 | Maintains | Neutral | |||
06/27/2024 | -54.16% | Jefferies | $14 → $23 | Maintains | Hold | |||
06/13/2024 | -48.19% | B of A Securities | $22 → $26 | Maintains | Buy | |||
06/03/2024 | -56.16% | B of A Securities | $17.25 → $22 | Maintains | Buy | |||
05/22/2024 | -52.17% | Canaccord Genuity | $20 → $24 | Maintains | Buy | |||
05/22/2024 | -60.14% | Citigroup | $16 → $20 | Downgrade | Buy → Neutral | |||
05/07/2024 | -68.11% | Deutsche Bank | $14 → $16 | Maintains | Hold | |||
05/07/2024 | -74.09% | Piper Sandler | $11 → $13 | Maintains | Neutral | |||
04/16/2024 | -70.11% | Jefferies | $17 → $15 | Downgrade | Buy → Hold | |||
04/10/2024 | -60.14% | Canaccord Genuity | → $20 | Initiates | → Buy | |||
02/27/2024 | -66.12% | Guggenheim | $15 → $17 | Maintains | Buy | |||
02/27/2024 | -68.11% | Citigroup | $12 → $16 | Maintains | Buy | |||
02/27/2024 | -78.08% | Piper Sandler | $9 → $11 | Maintains | Neutral | |||
02/27/2024 | -74.09% | Truist Securities | $10 → $13 | Maintains | Hold | |||
02/26/2024 | -80.07% | Leerink Partners | → $10 | Initiates | → Market Perform | |||
01/05/2024 | -70.11% | Tigress Financial | $14 → $15 | Maintains | Buy | |||
08/09/2023 | -80.07% | Truist Securities | $12 → $10 | Maintains | Hold | |||
08/08/2023 | -72.1% | Credit Suisse | → $14 | Reiterates | Outperform → Outperform | |||
07/28/2023 | -78.08% | TD Cowen | → $11 | Initiates | → Outperform | |||
06/15/2023 | -72.1% | Tigress Financial | $12 → $14 | Reiterates | → Buy | |||
05/30/2023 | -78.08% | Piper Sandler | $12 → $11 | Maintains | Neutral | |||
05/09/2023 | -70.11% | B of A Securities | $13.5 → $15 | Maintains | Buy | |||
05/09/2023 | -76.09% | Piper Sandler | $11 → $12 | Maintains | Neutral | |||
04/27/2023 | -64.13% | Guggenheim | $15 → $18 | Maintains | Buy | |||
04/26/2023 | -78.08% | Piper Sandler | $10 → $11 | Maintains | Neutral | |||
04/11/2023 | -80.07% | Baird | → $10 | Initiates | → Neutral | |||
03/01/2023 | -72.1% | Credit Suisse | $8 → $14 | Maintains | Outperform | |||
02/28/2023 | -70.11% | Guggenheim | → $15 | Reiterates | → Buy | |||
02/28/2023 | -76.09% | Truist Securities | $7 → $12 | Maintains | Hold | |||
02/28/2023 | -72.1% | Citigroup | $9 → $14 | Maintains | Buy | |||
02/28/2023 | -80.07% | Piper Sandler | $7 → $10 | Maintains | Neutral | |||
02/28/2023 | -73.1% | B of A Securities | $11.5 → $13.5 | Maintains | Buy | |||
02/09/2023 | -78.08% | Jefferies | $7 → $11 | Upgrade | Hold → Buy | |||
01/12/2023 | -76.09% | Tigress Financial | $11 → $12 | Maintains | Buy | |||
11/08/2022 | -83.06% | B of A Securities | $7.5 → $8.5 | Upgrade | Neutral → Buy | |||
11/08/2022 | — | SVB Leerink | — | Upgrade | Underperform → Market Perform | |||
10/17/2022 | -88.04% | Piper Sandler | $8 → $6 | Downgrade | Overweight → Neutral |
FAQ
Quel est le cours indicatif de l'action Hims & Hers Health (HIMS) ?
Le dernier objectif de prix pour Hims & Hers Health (NYSE:HIMS) a été rapporté par Truist Securities le août 18, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $37.00 s'attendant à ce que HIMS se fall dans les 12 prochains mois (un possible changement de -26.24% downside). 39 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Hims & Hers Health (HIMS) ?
La dernière note d'analyste pour Hims & Hers Health (NYSE:HIMS) a été fournie par Truist Securities, et Hims & Hers Health maintenu leur note hold.
Quand a eu lieu la dernière mise à niveau pour Hims & Hers Health (HIMS) ?
La dernière amélioration pour Hims & Hers Health Inc a eu lieu le février 9, 2023 lorsque Jefferies a augmenté leur objectif de prix à $11. Jefferies avait précédemment a hold pour Hims & Hers Health Inc.
Quand a eu lieu la dernière dégradation pour Hims & Hers Health (HIMS) ?
La dernière réduction pour Hims & Hers Health Inc a eu lieu le avril 29, 2025 lorsque TD Cowen a changé leur objectif de prix de $44 à $30 pour Hims & Hers Health Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Hims & Hers Health (HIMS) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Hims & Hers Health, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Hims & Hers Health a été déposée le août 18, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 18, 2026.
La note d'analyste pour Hims & Hers Health (HIMS) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Hims & Hers Health (HIMS) était un maintenu avec un objectif de prix de $48.00 à $37.00. Le prix actuel de Hims & Hers Health (HIMS) est de $50.17, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.